SEC Filing Summary
Filing identity: The supplied filing is Ekso Bionics Holdings, Inc.’s Form 10-Q, not a filing for Chronoscale Holdings Corp. It covers the quarter ended March 31, 2020; financial amounts below are in thousands of dollars unless stated otherwise.
Business context and reporting period
Ekso designs and sells exoskeletons for medical rehabilitation (EksoHealth) and industrial uses (EksoWorks). The unaudited results are for the first quarter of 2020, compared with the first quarter of 2019. The company completed a 1-for-15 reverse stock split on March 24, 2020.
Financial performance and liquidity
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Revenue | $1,468 | $3,616 | Down 59% |
| Gross profit | $637 | $1,599 | Down 60% |
| Gross margin | 43.4% | 44.2% | Down 0.8 percentage points |
| Operating expenses | $5,418 | $6,511 | Down 17% |
| Operating loss | $(4,781) | $(4,912) | Loss narrowed $131 |
| Net loss | $(2,534) | $(6,551) | Loss narrowed $4,017 |
| Basic and diluted loss per share | $(0.44) | $(1.51) | |
| Cash used in operating activities | $(1,722) | $(5,177) | Use decreased $3,455 |
Revenue fell mainly because customers delayed device orders amid COVID-19 disruption. EksoHealth revenue was $1,191, down from $2,814; EksoWorks revenue was $277, down from $802. Gross margin was approximately 43.4%, versus 44.2% a year earlier.
Net loss included a $2,519 noncash gain from revaluing warrant liabilities, compared with a $1,122 revaluation loss in Q1 2019. This fair-value change materially improved reported net loss and does not represent operating cash generation.
Cash was $8,516 at quarter-end, down from $10,872 at December 31, 2019. The debt covenant then required $3,565 of minimum cash, leaving estimated unrestricted cash of $4,951. Current assets were $14,062 and current liabilities $7,550. Term-loan carrying value was $2,170; contractual principal and interest obligations were reported as $2,249. Total liabilities were $11,716 and stockholders’ equity was $5,228.
Material changes and management commentary
- Revenue declined $2,148, primarily from lower device sales in both segments as customers shifted attention to pandemic response and delayed orders.
- Operating expenses decreased $1,093, reflecting lower marketing and trade-show activity, completion of the main clinical trial, reduced patent and licensing costs, lower headcount, and cost-efficiency initiatives.
- Operating cash use improved year over year, with management citing expense reductions and increased accounts-receivable collections.
- Management reported new pilot programs with two network operators in March and said many customers still expected to place orders, while noting uncertainty about the timing of recovery.
Outlook, risks, and unusual items
- Going concern: Management stated that forecast cash would not fund operations for the 12 months after issuance, raising substantial doubt about the company’s ability to continue as a going concern. It believed resources would support covenant compliance only through the end of Q4 2020, assuming modest revenue increases. Additional financing is needed; availability and terms are uncertain, and equity financing could dilute shareholders.
- COVID-19: The pandemic disrupted customer orders, supply chains, and operations. The company furloughed part of its workforce and temporarily closed its headquarters. Management anticipated an impact at least through the period ended June 30, 2020, but said the full effect was unclear. No specific revenue or earnings guidance was provided.
- Subsequent financing actions: On April 20, 2020, the company obtained a $1,086 Paycheck Protection Program loan at 1% interest, potentially subject to forgiveness; forgiveness was not assured. On April 29, it amended its term loan to defer principal payments for May through July 2020, with interest-only payments during that period and principal payments resuming August 1. The amendment replaced the cash-burn covenant with a minimum-liquidity covenant requiring cash at the lender at least equal to the loan balance.
- China joint venture: CFIUS review remained unresolved. Interim measures imposed in February 2020 suspended company contributions and other integration activities. U.S. government action could delay, restrict, or unwind the venture and related technology transfers.
- Other items: The company regained Nasdaq minimum-bid-price compliance on April 7 after its reverse split, but continued compliance was not assured. The company disclosed $881 of purchase obligations due within a year and no pending legal proceedings expected to have a material adverse effect.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Ekso Bionics Holdings, Inc., whereas the request names Chronoscale Holdings Corp.
- Track cash burn, unrestricted cash, financing progress, and compliance with the amended lender liquidity covenant.
- Assess whether revenue and customer orders recover after pandemic-related delays, including by segment.
- Separate operating performance from the noncash warrant revaluation gain when evaluating the smaller net loss.
- Check the outcome of CFIUS review and any resulting restrictions on the China joint venture or technology transfers.
- Confirm the PPP loan’s ultimate forgiveness status and the effect of deferred loan principal payments on liquidity.